Get startedLog in
    Picture of SciClone Pharmaceuticals (Holdings) logo

    6600 — SciClone Pharmaceuticals (Holdings) News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareSpeculativeMid Cap
    All News

    Brief: Sciclone Pharmaceuticals NMPA Grants Priority Review To BLA Of Danyelza (Naxitamab)

    Picture of SciClone Pharmaceuticals (Holdings) logoSciClone Pharmaceuticals (Holdings)
    10/09/2021 13:51
    Sept 10 (Reuters) - SciClone Pharmaceuticals (Holdings) Ltd
 6600.HK :
    * NMPA GRANTS PRIORITY REVIEW TO BLA OF DANYELZA (NAXITAMAB)

Source text for Eikon:  ID:nHKS84hTsN 
Further company coverage:  6600.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on SciClone Pharmaceuticals (Holdings)

    See all news